Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced the wholesale acquisition cost (WAC) for AMPYRA™
(dalfampridine) Extended Release Tablets will be $1,056 per 30-day
supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was
approved on January 22, 2010 by the U.S. Food and Drug Administration
(FDA) as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an increase in walking speed.
AMPYRA is expected to be available in March 2010.
“To that end, our
assistance programs account for people who are unable to afford their
medications but whose income or healthcare coverage often exclude them
from other patient assistance programs. And regardless of income, people
with private insurance can benefit from our co-pay program, wherever
allowed by law.”
Acorda is launching a comprehensive set of services to ensure broad
access to AMPYRA for people with MS, including patient assistance and
co-pay programs that will be open as soon as AMPYRA is commercially
available.
“AMPYRA is the first medication indicated to improve walking in people
with MS, one of the most debilitating challenges associated with the
disease. Acorda’s goal is to ensure that cost is not a barrier to any
person with MS who may benefit from this important medication,
regardless of their level of income or healthcare coverage,” said Ron
Cohen, M.D., President and CEO of Acorda Therapeutics. “To that end, our
assistance programs account for people who are unable to afford their
medications but whose income or healthcare coverage often exclude them
from other patient assistance programs. And regardless of income, people
with private insurance can benefit from our co-pay program, wherever
allowed by law.”
AMPYRA Patient Support Services